Spleen Tyrosine Kinase Inhibitors Pipeline Market Research Report 2022 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Spleen tyrosine kinase inhibitors – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Spleen tyrosine kinase inhibitors – Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen tyrosine kinase inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Spleen tyrosine kinase inhibitors: Overview

Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk inhibitors are a new group of small molecule inhibitors targeting BCR-mediated signaling pathways.

Syk was recognized as a critical element in the BCR signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk along with other BCR signaling molecules, Bruton tyrosine kinase (BTK), PI3K delta (PI3Kδ), and tumor necrosis factor (TNF) superfamily receptors was also found to be involved in signal transduction independent from the BCR.

Syk is expressed primarily in hematopoietic cells like B-cells, monocytes, macrophages, mast cells, and neutrophils. Syk was recognized to be a potential target for the treatment of various hematologic cancers, autoimmune disorders, and other inflammatory states.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Spleen tyrosine kinase inhibitors R&D. The therapies under development are focused on novel approaches for Spleen tyrosine kinase inhibitors.

Spleen tyrosine kinase inhibitors Emerging Drugs Chapters

This segment of the Spleen tyrosine kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spleen tyrosine kinase inhibitors Emerging Drugs

Fostamatinib: Rigel Pharmaceuticals

Fostamatinib is a selective, oral spleen tyrosine kinase (SYK) inhibitor being evaluated for Autoimmune haemolytic anaemia, COVID-19 which is currently in Phase III stage of development and is being developed by Rigel Pharmaceuticals.

Entospletinib: Kronos Bio

Entospletinib (ENTO), is a selective inhibitor targeting SYK, a critical node in a dysregulated TRN within AML defined by persistent high expression of the transcription factors HOXA9 and MEIS1 (HOX/MEIS). It is currently in Phase II stage of development for the treatment of Acute myeloid leukaemia and is being developed by Kronos Bio.

Major Players working on Spleen tyrosine kinase inhibitors

There are approx. 10+ key companies which are developing the Spleen tyrosine kinase inhibitors. The companies which have their Spleen tyrosine kinase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Rigel Pharmaceuticals.

Key Players

• Dermavant Sciences
• Rigel Pharmaceuticals
• Kronos Bio
• Hutchison MediPharma
• Hanmi Pharmaceutical
• Genosco
• Asana BioSciences

Key Products

• Cerdulatinib
• Fostamatinib
• Entospletinib
• Lanraplenib
• HMPL-523
• HM43239
• SKI O 703
• ASN002

Key Topics Covered:

Introduction

Executive Summary

Spleen tyrosine kinase inhibitors: Overview

• Structure
• Mechanism of Action

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

• Comparative Analysis

Fostamatinib: Rigel Pharmaceuticals

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

Entospletinib: Kronos Bio

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I/II)

• Comparative Analysis

HM43239: Hanmi Pharmaceutical

• Product Description
• Research and Development
• Product Development Activities

Preclinical and Discovery Stage Products

• Comparative Analysis

Drug Name: Company Name

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Spleen tyrosine kinase inhibitors Key Companies

Spleen tyrosine kinase inhibitors Key Products

Spleen tyrosine kinase inhibitors- Unmet Needs

Spleen tyrosine kinase inhibitors- Market Drivers and Barriers

Spleen tyrosine kinase inhibitors- Future Perspectives and Conclusion

Spleen tyrosine kinase inhibitors Analyst Views

Spleen tyrosine kinase inhibitors Key Companies

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/24lem8

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900